TITLE

MORPHOSYS.PFIZER TO DEVLOP THERAPEUTIC ANTIBODIES

PUB. DATE
February 2004
SOURCE
Worldwide Biotech;Feb2004, Vol. 16 Issue 2, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a collaboration of MorphoSys AG with Pfizer Inc. for the development of therapeutic antibodies.
ACCESSION #
12067824

 

Related Articles

  • New listings on European stock market. Michael, Adam // Nature Biotechnology;May99, Vol. 17 Issue 5, p410 

    Reports on the listing of Munich, Germany-based biotechnology company MorphoSys AG in Neuer Markt. Initial public offering of the company; Postponement of the listing of BioVector Therapeutics SA.

  • European Patent Issues for Antibody Technology.  // Drug Discovery & Development;Jul/Aug2002, Vol. 5 Issue 7, p19 

    Reports on the patent granted by the European Patent Office to MorphoSys AG covering the Human Combinatorial Antibody Library in Germany.

  • Return of the Neuer Markt. F├╝rst, Ingeborg // Nature Biotechnology;Mar1999, Vol. 17 Issue 3, p222 

    Reports that Morphosys AG and MWG Biotech have filed initial public offerings with the Neuer Markt in Frankfurt, Germany as of March 1999. Corporate background of the companies; Overview of the Neuer Markt; Possible problems faced by the Neuer Markt.

  • Morphosys - MorphoSys Raises EUR 115 million in Private Placement.  // Acquisdata Industry SnapShot Germany Pharmaceuticals;11/23/2016, Issue 6401, p6 

    The article reports on the gross proceeds raised by German biotechnology company MorphoSys AG of approximately 115 million euros in a private placement via an accelerated book building transaction.

  • Clinic Roundup.  // BioWorld Today;12/3/2010, Vol. 21 Issue 233, p2 

    This section offers news briefs related to clinical trials as of December 2010, including the enrollment of first patient in Geron Corporation's Phase II trial of imetelstat with paclitaxel for metastatic breast cancer, a Phase I trial of MOR208 by Morphosys AG for the treatment of chronic...

  • Other News To Note.  // BioWorld Today;5/2/2011, Vol. 22 Issue 84, p5 

    This section offers news briefs concerning the biotechnology industry, including the withdrawal of a drug application by Centocor Ortho Biotech Inc., the strategic review process of Labopharm Inc. and a milestone payment for MorphoSys AG.

  • MorphoSys and Xencor Collaborate on Potential Rituxan Competitor.  // BioPharm International;Aug2010, Vol. 23 Issue 8, p14 

    The article reports on the exclusive worldwide license provided to MorphoSys AG to XmAb5574, a monoclonal antibody developed by Xencor Inc., for the treatment of B-cell malignancies.

  • Genedata licences data management platform to MorphoSys.  // Scientific Computing World;Dec2011/Jan2012, Issue 121, p4 

    The article reports on the plan of MorphoSys AG to issue permit for Genedata Biologics as its research and development (R&D) data management scheme.

  • HuCAL Antibody Combats Alzheimer's Disease. Sproll, Marlies // Drug Discovery & Development;Oct2010, Vol. 13 Issue 8, p14 

    The article offers information on the findings of the collaborative research by Roche and MorphoSys Ag on the use of Human Combinatorial Antibody Library (HuCAL) to fight the Alzheimer's disease wherein it indicates the high specificity of the HuCAl antibody.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics